Predictors for Adherence to Recommended Anticoagulation after Stroke Unit Discharge in Patients with Atrial

PubMed

Insights

High adherence to anticoagulation after stroke is achieved by starting medication during hospitalization and clearly documenting the anticoagulant choice. This simplifies management for patients with atrial fibrillation (AF).

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Non-adherence to secondary preventive anticoagulation in stroke patients with atrial fibrillation (AF) is a significant clinical challenge.
  • Direct oral anticoagulants (DOACs) have improved anticoagulation management, yet adherence remains suboptimal.
  • Understanding predictors of adherence is crucial for optimizing secondary stroke prevention in AF patients.

Purpose of the Study:

  • To examine the adherence rates of secondary preventive anticoagulation in AF patients post-stroke.
  • To identify predictors for adherence and non-adherence to anticoagulation therapy.
  • To analyze obstacles hindering anticoagulation implementation in the post-stroke rehabilitation phase.

Main Methods:

  • A telephone survey was conducted with AF patients 6-12 weeks post-stroke.
  • Analysis included discharge letters from rehabilitation clinics for patients not on anticoagulation.
  • Data were collected from patients treated between January 2013 and December 2021.

Main Results:

  • Anticoagulation was prescribed in 91.5% of 1348 evaluated patients, with 83.6% on DOACs.
  • Adherence was strongly associated with initiating anticoagulation at discharge, specific DOAC/dose recommendations, lower functional deficit (modified Rankin Scale), younger age, and absence of peripheral vascular disease.
  • Avoidable obstacles included non-implementation by rehabilitation physicians, delegation of initiation, and patient refusal due to disability.

Conclusions:

  • Initiating anticoagulation during stroke unit hospitalization and detailing the anticoagulant choice in discharge summaries significantly improves adherence.
  • Education of rehabilitation physicians and involvement of stroke specialists in post-stroke decision-making can mitigate avoidable non-adherence.
  • Addressing implementation gaps is key to maximizing secondary prevention in AF stroke patients.
Abstract

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
698
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K
Pre-Procedural Guidelines for Assessing Blood Pressure01:10

Pre-Procedural Guidelines for Assessing Blood Pressure

Accurate blood pressure assessment is crucial for diagnosing and managing various health conditions. To ensure the reliability of these measurements, healthcare professionals must adhere to standardized pre-procedural guidelines. These guidelines enhance patient safety and improve the overall quality of healthcare. The following steps are essential for obtaining accurate and consistent blood pressure readings, from using the appropriate tools to ensuring effective communication with the...
565
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
524